Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

I n 1876 Eli Lilly, a veteran of the civil war, founded a company in Indianapolis to bring scientific rigour to a medicines ...

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're ...

The weight loss tailwind isn't about to come to a halt.

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY) ...

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Mon, June 22, 2026 at 8:02 PM UTC Lilly is sprinting through an obesity gold rush. Pfizer is rebuilding after COVID and buying its way into the same race. Both beat estimates, but the businesses ...

Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score.